Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Stegelmann

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Deutsche Medizinische Wochenschrift (1946)|October 12, 2012
[Novel therapeutic options in the treatment of BCR/ABL-negative myeloproliferative neoplasms]K Döhner, F Stegelmann, R F Schlenk, et al.
Der Pathologe|July 16, 2015
[Detection of the BCR-ABL fusion: Comparative analysis of six commercially available FISH fusion probes]T Knas, M Buck, F Stegelmann, et al.
Leukemia|October 25, 2016
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosisR F Schlenk, F Stegelmann, A Reiter, et al.
Leukemia|February 14, 2015
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IVL Kalmanti, S Saussele, M Lauseker, et al.
Leukemia|May 7, 2014
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinibB Hanfstein, V Shlyakhto, M Lauseker, et al.
Leukemia|March 27, 2012
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)B Hanfstein, M C Müller, R Hehlmann, et al.
Leukemia|August 15, 2017
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsR Hehlmann, M Lauseker, S Saußele, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Deutsche Medizinische Wochenschrift (1946)|October 12, 2012
[Novel therapeutic options in the treatment of BCR/ABL-negative myeloproliferative neoplasms]K Döhner, F Stegelmann, R F Schlenk, et al.
Der Pathologe|July 16, 2015
[Detection of the BCR-ABL fusion: Comparative analysis of six commercially available FISH fusion probes]T Knas, M Buck, F Stegelmann, et al.
Leukemia|October 25, 2016
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosisR F Schlenk, F Stegelmann, A Reiter, et al.
Leukemia|February 14, 2015
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IVL Kalmanti, S Saussele, M Lauseker, et al.
Leukemia|May 7, 2014
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinibB Hanfstein, V Shlyakhto, M Lauseker, et al.
Leukemia|March 27, 2012
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)B Hanfstein, M C Müller, R Hehlmann, et al.
Leukemia|August 15, 2017
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsR Hehlmann, M Lauseker, S Saußele, et al.
Pageof 1